Edition:
United Kingdom

Morphosys AG (MORG.DE)

MORG.DE on Xetra

75.85EUR
4:35pm GMT
Change (% chg)

€0.25 (+0.33%)
Prev Close
€75.60
Open
€76.00
Day's High
€76.30
Day's Low
€75.15
Volume
59,167
Avg. Vol
154,976
52-wk High
€87.35
52-wk Low
€49.60

Select another date:

BRIEF-Morphosys Announces New Data On Tremfya

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

BRIEF-Morphosys Presents Clinical Data On MOR208 Plus Lenalidomide In Aggressive Lymphoma

* DGAP-NEWS: MORPHOSYS PRESENTS CLINICAL DATA ON MOR208 PLUS LENALIDOMIDE IN AGGRESSIVE LYMPHOMA (R/R DLBCL) AT ASH 2017 CONFERENCE

BRIEF-Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

BRIEF-Janssen receives approval for Tremfya in Europe - Morphosys

* Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis

BRIEF-Morphosys Q3 revenue up 20 pct at 15 mln eur​

* Q3 net loss -24 million eur versus -12.8 million eur loss year ago

BRIEF-Morphosys names Enzelberger as new chief scientific officer

* Says Dr. Markus Enzelberger appointed chief scientific officer

BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

* DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

Select another date: